Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892281 · ClinicalTrials.gov registry record · Phase 4
ORCA - Oracea® for Rosacea: A Community-based Assessment
A Phase 4 study of Rosacea, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,421
- Enrollment target
- 1
- Study location
NCT00892281 is a Phase 4 study of Rosacea that has completed, run by Galderma R&D. The registered enrollment target is 1,421 participants, above the 181-participant average among 23 other Rosacea trials with a reported enrollment target (685% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00892281, a Phase 4 study of Rosacea, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,421 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
Conditions Studied
Interventions
- DRUG doxycycline (Oracea®) 40 mg modified release as monotherapy
- DRUG doxycycline (Oracea®) 40 mg modified release as add-on therapy
Study Locations (1)
Kentucky
- REGISTRAT® - MAP1, Inc. (CRO) - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,421 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892281
The ClinicalTrials.gov registry entry for NCT00892281 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,421 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 181-participant average among 23 other Rosacea trials with a reported enrollment target (685% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which doxycycline (Oracea®) 40 mg modified release as monotherapy is the first listed.
NCT00892281 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT00892281 about?
NCT00892281 is a clinical study titled "ORCA - Oracea® for Rosacea: A Community-based Assessment". The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
What is the current status of trial NCT00892281?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,421 participants. The study started on 2009-04. Estimated completion is 2009-10.
What conditions does trial NCT00892281 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT00892281?
The interventions under investigation include: doxycycline (Oracea®) 40 mg modified release as monotherapy (DRUG), doxycycline (Oracea®) 40 mg modified release as add-on therapy (DRUG).
Who is sponsoring clinical trial NCT00892281?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00892281 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea
COMPLETED · Phase 4
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
Analysis of the Microbiome in Rosacea
ACTIVE NOT RECRUITING · Early Phase 1
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.